Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WGS Stock Forecast 2026-2027
$63.85
Current Price
$1.90B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to WGS Price Targets
+56.6%
To High Target of $100.00
+17.5%
To Median Target of $75.00
-13.9%
To Low Target of $55.00
WGS Price Momentum
-2.4%
1 Week Change
+6.6%
1 Month Change
-22.5%
1 Year Change
-50.9%
Year-to-Date Change
-62.6%
From 52W High of $170.87
+98.2%
From 52W Low of $32.21
📊 TOP ANALYST CALLS
Did WGS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sema4 is one of their latest high-conviction picks.
Latest WGS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, WGS has a bullish consensus with a median price target of $75.00 (ranging from $55.00 to $100.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $63.85, the median forecast implies a 17.5% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WGS Analyst Ratings
9
Buy
0
Hold
0
Sell
WGS Price Target Range
Low
$55.00
Average
$75.00
High
$100.00
Current: $63.85
Latest WGS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WGS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 29, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $74.00 |
| Jun 23, 2026 | Piper Sandler | David Westenberg | Overweight | Maintains | $63.00 |
| May 5, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 5, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 5, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| May 5, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 20, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 30, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Feb 24, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 24, 2026 | BTIG | Buy | Maintains | $N/A | |
| Feb 9, 2026 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Dec 22, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Dec 12, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 4, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Oct 29, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 29, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Oct 29, 2025 | BTIG | Buy | Maintains | $N/A | |
| Oct 22, 2025 | BTIG | Buy | Maintains | $N/A | |
| Oct 20, 2025 | Canaccord Genuity | Buy | Initiates | $N/A |
GeneDx Holdings Corp. (WGS) Competitors
The following stocks are similar to Sema4 based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GeneDx Holdings Corp. (WGS) Financial Data
GeneDx Holdings Corp. has a market capitalization of $1.90B with a P/E ratio of 724.6x. The company generates $442.68M in trailing twelve-month revenue with a -17.6% profit margin.
Revenue growth is +17.4% quarter-over-quarter, while maintaining an operating margin of -25.6% and return on equity of -30.4%.
Valuation Metrics
Market Cap
$1.90B
Enterprise Value
$1.95B
P/E Ratio
724.6x
PEG Ratio
0.9x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+17.4%
Gross Margin
+66.7%
Operating Margin
-25.6%
Net Margin
-17.6%
EPS Growth
+17.4%
Financial Health
Cash/Price Ratio
+9.0%
Current Ratio
3.1x
Debt/Equity
66.2x
ROE
-30.4%
ROA
-4.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
GeneDx Holdings Corp. (WGS) Business Model
About GeneDx Holdings Corp.
What They Do
Provides genetic testing for rare disorders.
Business Model
The company generates revenue by offering advanced genetic testing services, including whole exome and genome sequencing, targeted gene panels, and microarray testing. By leveraging a vast dataset and AI tools, GeneDx delivers precise clinical insights for healthcare providers, improving the speed and accuracy of diagnoses, which in turn enhances patient care and outcomes.
Additional Information
GeneDx is positioned in the growing field of precision medicine, addressing a range of genetic conditions and supporting both pediatric and adult patients. The company plays a critical role in reducing the time it takes to diagnose complex disorders and aids in drug discovery, appealing to a wide array of healthcare stakeholders.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,300
CEO
Ms. Katherine A. Stueland
Country
United States
IPO Year
2020
Website
www.genedx.comGeneDx Holdings Corp. (WGS) Latest News & Analysis
Latest News
Quick Summary
Faruqi & Faruqi's James Wilson is urging GeneDx investors who experienced losses to reach out for potential legal options regarding their investments.
Why It Matters
The call for investors impacted by GeneDx losses suggests potential legal action, which could influence stock performance and investor sentiment surrounding the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
GeneDx faces allegations of hiding deteriorating reimbursement rates and margin compression from investors, which may impact investor confidence and company valuation.
Why It Matters
Deteriorating reimbursement rates and margin compression could signal financial instability for GeneDx, impacting future profitability and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for securities violations. Investors who bought shares from April 16, 2025, to May 4, 2026, should contact Schall Law Firm by August 3, 2026.
Why It Matters
A class action lawsuit against GeneDx for securities violations could lead to financial penalties or settlements, impacting stock value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts investors of GeneDx Holdings Corp. (NASDAQ: WGS) that the lead plaintiff deadline for stock purchasers from April 16, 2025, to May 4, 2026, is August 3, 2026.
Why It Matters
The reminder of a lead plaintiff deadline indicates potential legal action against GeneDx Holdings, which may impact stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against GeneDx Holdings Corp. for alleged federal securities law violations during the period from April 16, 2025, to May 4, 2026.
Why It Matters
A class action lawsuit against GeneDx Holdings Corp. indicates potential legal and financial liabilities, which may negatively impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased shares from April 16, 2025, to May 4, 2026, have until August 3, 2026, to apply as lead plaintiff in a class action lawsuit.
Why It Matters
The announcement of a class action lawsuit against GeneDx Holdings may impact investor sentiment, potentially affecting stock price and trading volume as legal risks come into focus.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WGS Stock
What is GeneDx Holdings Corp.'s (WGS) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, GeneDx Holdings Corp. (WGS) has a median price target of $75.00. The highest price target is $100.00 and the lowest is $55.00.
Is WGS stock a good investment in 2027?
According to current analyst ratings, WGS has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $63.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WGS stock?
Wall Street analysts predict WGS stock could reach $75.00 in the next 12 months. This represents a 17.5% increase from the current price of $63.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GeneDx Holdings Corp.'s business model?
The company generates revenue by offering advanced genetic testing services, including whole exome and genome sequencing, targeted gene panels, and microarray testing. By leveraging a vast dataset and AI tools, GeneDx delivers precise clinical insights for healthcare providers, improving the speed and accuracy of diagnoses, which in turn enhances patient care and outcomes.
What is the highest forecasted price for WGS GeneDx Holdings Corp.?
The highest price target for WGS is $100.00 from at , which represents a 56.6% increase from the current price of $63.85.
What is the lowest forecasted price for WGS GeneDx Holdings Corp.?
The lowest price target for WGS is $55.00 from at , which represents a -13.9% decrease from the current price of $63.85.
What is the overall WGS consensus from analysts for GeneDx Holdings Corp.?
The overall analyst consensus for WGS is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $75.00.
How accurate are WGS stock price projections?
Stock price projections, including those for GeneDx Holdings Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 4:09 AM UTC